Dose-optimized stereotactic body radiotherapy for locally advanced or recurrent pancreatic andenocarcinoma

Recruiting

• Conditions: C25; Malignant neoplasm of pancreas

• Registration Number: DRKS00027912
• Lead Sponsor: ordstrahl

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Locally advanced pancreatic cancer
- recurrent pancreatic cancer

Exclusion Criteria

-previous Radiotherapy
-more advanced stadium than oligometastatic disease
-PTV more than 75 ml

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
freedom from local progression (FFLP)

Secondary Outcome Measures

Name	Time	Method
Quality of life<br>We will conduct the surveys at the following timepoints:<br>At the end of the radiotherapy<br>after 6 weeks<br>after 3 Months<br>further every 3 Months